QBW 251

Drug Profile

QBW 251

Alternative Names: NVP-QBW-251; QBW251

Latest Information Update: 08 Mar 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Novartis
  • Class Antifibrotics
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic obstructive pulmonary disease; Cystic fibrosis

Most Recent Events

  • 05 Apr 2017 Novartis plans regulatory filings for Cystic fibrosis in 2021
  • 29 Feb 2016 Novartis terminates a phase II trial in Cystic fibrosis in USA, Belgium, France, Germany, Ireland, Romania and the United Kingdom (NCT02190604)
  • 12 Jun 2015 Phase-II clinical trials in Chronic obstructive pulmonary disease in USA (PO) (NCT02449018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top